A lthough advanced stage aggressive non-Hodgkin'slymphomas and Hodgkin's disease are thought to be che-motherapy-responsive cancers, a considerable number of patients either relapse or never attain a remission...A lthough advanced stage aggressive non-Hodgkin'slymphomas and Hodgkin's disease are thought to be che-motherapy-responsive cancers, a considerable number of patients either relapse or never attain a remission. High-dose therapy(HDT) followed by autologous stem cell transplantation(ASCT) is often the only possibility of cure for most of these patients. However, many controversial issues still remain with respect to HDT/ASCT for lymphomas, including its role for, the optimal timing of transplantation, the best conditioning regimen and the potential use of localized radiotherapy or immunologic methods to decrease post-transplant recurrence. Recently, mainly due to the unavailability of carmustine, several novel conditioning protocols have been clinically developed, with the aim of improving the overall outcome by enhancing the anti-lymphoma effect and, at the same time, by reducing short and long-term toxicity. Furthermore, the better safety profiles of novel approaches would definitively allow patients aged more than 65-70 years to benefit from this therapeutic option. In this review, we will briefly discuss the most relevant and recent data available regarding HDT/ASCT in lymphomas.展开更多
为明确胃肠道原发NHL特别是MALT淋巴瘤的发病特征及组织学起源,本研究使用LN_(1～3)系列抗体对34例胃肠道原发NHL进行免疫组化检测。结果显示:34例中MALT淋巴瘤5例(14.7％),其中3例由滤泡中心细胞样细胞构成,另2例由中心母细胞样细胞构...为明确胃肠道原发NHL特别是MALT淋巴瘤的发病特征及组织学起源,本研究使用LN_(1～3)系列抗体对34例胃肠道原发NHL进行免疫组化检测。结果显示:34例中MALT淋巴瘤5例(14.7％),其中3例由滤泡中心细胞样细胞构成,另2例由中心母细胞样细胞构成。肿瘤细胞在LN_1显示核周边点状阳性,LN_2显示核膜线状阳性,与正常肠道Peyet板僧帽带处的Marginal zone cell具有相似的形态及染色特性,提示MALT淋巴瘤可能来源于Marginal zone cells。展开更多
目的探讨程序性死亡受体1(PD1)及半胱氨酸天门冬氨酰蛋白酶(cysteine aspartyl protease,Caspasee)募集域家族成员11(caspase recruitment domain family member 11,CARD11)表达与弥漫大B细胞淋巴瘤(DLBCL)患者远期生存的关系。方法选取...目的探讨程序性死亡受体1(PD1)及半胱氨酸天门冬氨酰蛋白酶(cysteine aspartyl protease,Caspasee)募集域家族成员11(caspase recruitment domain family member 11,CARD11)表达与弥漫大B细胞淋巴瘤(DLBCL)患者远期生存的关系。方法选取2012年2月-2014年12月期间唐山市人民医院收治DLBCL患者80例作为本文研究对象,免疫组化法检测淋巴结病理组织PD1和CARD11,分析二者与临床病理参数的关系,采用单因素和多因素Cox回归模型,探讨PD1和CARD11与DLBCL患者远期生存的关系。结果80例DLBCL患者中CARD11阳性为52例,阳性率为65.00%;PD1阳性为44例,阳性率为55.00%;DLBCL患者五年生存率与年龄、Ann Arbor分期、临床疗效、结外累及数目、国际预后指数(IPI)评分、B症状、病理亚型、PD1表达和CARD11表达均有统计学差异(P<0.05);Cox回归分析结果显示Ann-Arbor分期(Ⅲ~Ⅳ)(OR=1.351,95%CI:1.081~1.690)、临床疗效(无效)(OR=1.972,95%CI:1.029~3.780)、年龄(>60岁)(OR=1.473,95%CI:1.182~1.834)、PD1阳性表达(OR=2.399,95%CI:1.892~3.041)和CARD11阳性表达(OR=2.010,95%CI:1.435~2.815)是DLB⁃CL患者5年生存率的独立危险因素(P<0.05)。结论PD1和CARD11均在DLBCL淋巴结病理组织中表达,且是远期生存的独立危险因素,可作为DLBCL患者预后评估有效指标。展开更多
目的研究PET/CT诊断结外淋巴瘤的临床应用价值。方法应用G EDiscovery LS PET/CT扫描机,对42例淋巴瘤患者进行18F-F D G代谢显像,对其中15例(非霍奇金淋巴瘤non Hodgkin lympooma,NHL,13例,霍奇金淋巴瘤Hodgkin lympooma,H L,2例)原发和...目的研究PET/CT诊断结外淋巴瘤的临床应用价值。方法应用G EDiscovery LS PET/CT扫描机,对42例淋巴瘤患者进行18F-F D G代谢显像,对其中15例(非霍奇金淋巴瘤non Hodgkin lympooma,NHL,13例,霍奇金淋巴瘤Hodgkin lympooma,H L,2例)原发和/或继发结外淋巴瘤的显像结果进行定性和半定量分析,并与C T扫描结果进行比较,病理学诊断为金标准。结果PET/CT代谢显像发现15例结外淋巴瘤中20个18F-F D G摄取异常增高病灶,其对结外淋巴瘤病灶的探测的P E T/C T显像灵敏度、特异性、准确率分别为90%、100%、91%;CT显像检出9个真阳性病灶,2个真阴性病灶,灵敏度、特异性、准确率分别为35%、100%、41%。CT与PET/CT检查的一致性为45%。结论PET/CT18F-F D G代谢显像对结外淋巴瘤具有重要的临床诊断价值。展开更多
文摘A lthough advanced stage aggressive non-Hodgkin'slymphomas and Hodgkin's disease are thought to be che-motherapy-responsive cancers, a considerable number of patients either relapse or never attain a remission. High-dose therapy(HDT) followed by autologous stem cell transplantation(ASCT) is often the only possibility of cure for most of these patients. However, many controversial issues still remain with respect to HDT/ASCT for lymphomas, including its role for, the optimal timing of transplantation, the best conditioning regimen and the potential use of localized radiotherapy or immunologic methods to decrease post-transplant recurrence. Recently, mainly due to the unavailability of carmustine, several novel conditioning protocols have been clinically developed, with the aim of improving the overall outcome by enhancing the anti-lymphoma effect and, at the same time, by reducing short and long-term toxicity. Furthermore, the better safety profiles of novel approaches would definitively allow patients aged more than 65-70 years to benefit from this therapeutic option. In this review, we will briefly discuss the most relevant and recent data available regarding HDT/ASCT in lymphomas.
文摘为明确胃肠道原发NHL特别是MALT淋巴瘤的发病特征及组织学起源,本研究使用LN_(1～3)系列抗体对34例胃肠道原发NHL进行免疫组化检测。结果显示:34例中MALT淋巴瘤5例(14.7％),其中3例由滤泡中心细胞样细胞构成,另2例由中心母细胞样细胞构成。肿瘤细胞在LN_1显示核周边点状阳性,LN_2显示核膜线状阳性,与正常肠道Peyet板僧帽带处的Marginal zone cell具有相似的形态及染色特性,提示MALT淋巴瘤可能来源于Marginal zone cells。
文摘目的探讨程序性死亡受体1(PD1)及半胱氨酸天门冬氨酰蛋白酶(cysteine aspartyl protease,Caspasee)募集域家族成员11(caspase recruitment domain family member 11,CARD11)表达与弥漫大B细胞淋巴瘤(DLBCL)患者远期生存的关系。方法选取2012年2月-2014年12月期间唐山市人民医院收治DLBCL患者80例作为本文研究对象,免疫组化法检测淋巴结病理组织PD1和CARD11,分析二者与临床病理参数的关系,采用单因素和多因素Cox回归模型,探讨PD1和CARD11与DLBCL患者远期生存的关系。结果80例DLBCL患者中CARD11阳性为52例,阳性率为65.00%;PD1阳性为44例,阳性率为55.00%;DLBCL患者五年生存率与年龄、Ann Arbor分期、临床疗效、结外累及数目、国际预后指数(IPI)评分、B症状、病理亚型、PD1表达和CARD11表达均有统计学差异(P<0.05);Cox回归分析结果显示Ann-Arbor分期(Ⅲ~Ⅳ)(OR=1.351,95%CI:1.081~1.690)、临床疗效(无效)(OR=1.972,95%CI:1.029~3.780)、年龄(>60岁)(OR=1.473,95%CI:1.182~1.834)、PD1阳性表达(OR=2.399,95%CI:1.892~3.041)和CARD11阳性表达(OR=2.010,95%CI:1.435~2.815)是DLB⁃CL患者5年生存率的独立危险因素(P<0.05)。结论PD1和CARD11均在DLBCL淋巴结病理组织中表达,且是远期生存的独立危险因素,可作为DLBCL患者预后评估有效指标。
文摘目的研究PET/CT诊断结外淋巴瘤的临床应用价值。方法应用G EDiscovery LS PET/CT扫描机,对42例淋巴瘤患者进行18F-F D G代谢显像,对其中15例(非霍奇金淋巴瘤non Hodgkin lympooma,NHL,13例,霍奇金淋巴瘤Hodgkin lympooma,H L,2例)原发和/或继发结外淋巴瘤的显像结果进行定性和半定量分析,并与C T扫描结果进行比较,病理学诊断为金标准。结果PET/CT代谢显像发现15例结外淋巴瘤中20个18F-F D G摄取异常增高病灶,其对结外淋巴瘤病灶的探测的P E T/C T显像灵敏度、特异性、准确率分别为90%、100%、91%;CT显像检出9个真阳性病灶,2个真阴性病灶,灵敏度、特异性、准确率分别为35%、100%、41%。CT与PET/CT检查的一致性为45%。结论PET/CT18F-F D G代谢显像对结外淋巴瘤具有重要的临床诊断价值。
